Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro

PeerJ

article

Xinyue Wang¹  Songyi Qian²  Siyi Wang¹  Sheng Jia¹  Nishang Zheng¹  Qing Yao¹  Jian Gao³ 

[1] Department of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital ,(Xiamen), Fudan University, Xiamen, Fujian province;Department of Cardiac Surgery, Zhongshan Hospital ,(Xiamen), Fudan University, Xiamen, Fujian province;Department of Nutrition, Zhongshan Hospital, Fudan University

关键词: Vitamin C;    Lenvatinib;    Proliferation;    Migration;    Invasion;   

DOI  :  10.7717/peerj.14610

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

Lenvatinib has become a first-line drug in the treatment of advanced hepatocellular carcinoma (HCC). Investigating its use in combination with other agents is of great significance to improve the sensitivity and durable response of Lenvatinib in advanced HCC patients. Vitamin C (L-ascorbic acid, ascorbate, VC) is an important natural antioxidant, which has been reported to show suppressive effects in cancer treatment. Here, we investigated the effect of the combination of VC and Lenvatinib in HCC cells in vitro. We found that treatment of VC alone significantly inhibited the proliferation, migration and invasion in HCC cells. Additionally, VC was strongly synergistic with Lenvatinib in inhibition of the proliferative, migratory and invasive capacities of HCC cells in vitro. In conclusion, our results demonstrate that the combination of VC and Lenvatinib has synergistic antitumor activities against HCC cells, providing a promising therapeutic strategy to improve the prognosis of HCC patients.

【 授权许可】

CC BY